From the publisher feed
The FDA said it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
Read the original at STAT ↗Opens the original publisher page. Access, copyright and subscriptions are controlled by the publisher.
A useful next step
- Read the short publisher description here.
- Open the full report directly at the publisher.
- Compare this topic with other sources when useful.